原发灶不明转移癌基因表达谱分析技术进展

doi:10.11904/j.issn.1002-3070.2017.06.014

摘要/Abstract

摘要： 原发灶不明转移癌(CUP)是一类经组织病理学证实为转移性,但经多种临床诊疗手段无法明确原发灶的肿瘤。明确肿瘤原发部位是CUP诊断的第一步,组织病理学、免疫组织化学技术、PET/CT都是临床常用的诊疗手段。基因表达谱分析技术是近年新兴的一种诊断原发灶的方法,具有较高的诊断准确率、敏感性和特异性,有望实现CUP患者的个体化治疗。

关键词: 原发灶不明转移癌, 基因表达谱分析技术, 诊断进展

Abstract: Primary lesions unknown metastatic cancer (CUP)is a class of histopathologically confirmed metastases.However,a variety of clinical diagnosis and treatment can not clear the primary tumor.The identification of tumor primary site is the first step in the diagnosis of CUP.The histopathology,immunohistochemistry and PET /CT are commonly used clinical diagnosis and treatment.Gene expression profiling technique is a new method for the diagnosis of primary tumor in recent years.It has high diagnostic accuracy,sensitivity and specificity,and is expected to achieve individual treatment of patients with CUP.

Key words: Cancer of unknown primary sites(CUP), Gene expression profiling(GEP), Progress in diagnosis

中图分类号:

韩倩, 林连君, 刘新民校审. 原发灶不明转移癌基因表达谱分析技术进展[J]. 实用肿瘤学杂志, 2017, 31(6): 554-558.

HAN Qian, LIN Lianjun, LIU Xinmin. Advances in gene expression profiling of metastases from unidentified primary tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 554-558.

参考文献

1 National Comprehensive Cancer Network.Clinical Practice Guidelines in Oncology.Occult primary(cancer of unknown primary[CUP]),version 2.2016[M/OL].https://www.nccn.org/professionals/physician_gls/f_guidelines.asp,2016.
2 Greco FA.Cancer of unknown primary site:still an entity,a biological mystery and a metastatic model[J].Nat Rev Cancer,2014,14(1):3-4.
3 Hainsworth JD,Greco FA.Gene expression profiling in patients with carcinoma of unknown primary site:from translational research to standard of care[J].Virchows Arch,2014,464(4):393-402.
4 Wang G,Wu Y,Zhang W,et al.Clinical value of whole-body ¹⁸F fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary[J].J Med Imaging Radiat Oncol,2013,57(1):65-71.
5 Riaz S,Nawaz MK,Faruqui ZS,et al.Diagnostic accuracy of ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography in the evaluation of carcinoma of unknown primary[J].Mol Imaging Radionucl Ther,2016,25(1):11-18.
6 Hemminki K,Liu H,Heminki A,et al.Power and limits of modern cancer diagnostics:cancer of unknown primary[J].Ann Oncol,2012,23(3):760-764.
7 Burglin SA,Hess S,Hoilund-carlsen PF,et al.¹⁸F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary:A systematic review and meta-analysis[J].Medicine,2017,96(16):e6713.
8 Varadhachary GR,Raber MN.Cancer of unknown primary site[J].N Engl J Med,2014,371(8):757-765.
9 Pentheroudakis G,Spector Y,Krikelis D,et al.Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary(CUP)demonstrates no significant expression differences with metastases of matched known primary tumors[J].Clin Exp Metastasis,2013,30(4):431-439.
10 Ma XJ,Patel R,Wang X,et al.Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay[J].Arch Pathol Lab Med,2006,130(4):465-473.
11 Tothill RW,Shi F,Paiman L,et al.Development and validation of a gene expression tumour classifier for cancer of unknown primary[J].Pathology,2015,47(1):7-12.
12 Brachtel EF,Operana TN,Suillivan PS,et al.Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples[J].Oncotarget,2016,7(19):27220-27231.
13 Monzon FA,Lyons-weiler M,Buturovic LJ,et al.Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin[J].J Clin Oncol,2009,27(15):2503-2508.
14 Horlings HM,Vanlaar RK,Kerst JM,et al.Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary[J].J Clin Oncol,2008,26(27):4435-4441.
15 Rosenfeld N,Aharonov R,Meiri E,et al.MicroRNAs accurately identify cancer tissue origin[J].Nat Biotechnol,2008,26(4):462-469.
16 Solilde R,Vincent M,Moller AK,et al.Efficient identification of miRNAs for classification of tumor origin[J].J Mol Diagn,2014,16(1):106-115.
17 Ferracin M,Pedriali M,Veronese A,et al.MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin[J].J Pathol,2011,225(1):43-53.
18 Meiri E,Mueller WC,Rosenwald S,et al.A second-generation microRNA-based assay for diagnosing tumor tissue origin[J].The Oncologist,2012,17(6):801-8012.
19 Pentheroueakis G,Pavlidis N,Fountzilas G,et al.Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary[J].Mol Cancer,2013,12(57):1-8.
20 Moran S,Arribas C,Esteller M.Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences[J].Epigenomics,2016,8(3):389-399.
21 Elizabeth M,Matthew LZ,Yang ZH,et al.A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells[J].Oncotarget,2015,7(4):15.
22 Economopoulou P,Mountzios G,Pavlidis N,et al.Cancer of unknown primary origin in the genomic era: Elucidating the dark box of cancer[J].Cancer Treat Rev,2015,41(7):598-604.
23 Handorf CR,Kulkarni A,Grenert JP,et al.A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors[J].Am J Surg Pathol,2013,37(7):1067-1075.
24 Greco FA,Lennington WJ,Spigel DR,et al.Poorly differentiated neoplasms of unknown primary site:diagnostic usefulness of a molecular cancer classifier assay[J].Mol Diagn Ther,2015,19(2):91-97.
25 Weiss LM,Chu P,Schroeder BE,et al.Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors[J].J Mol Diagn,2013,15(2):263-269.
26 Greco FA,Lennington WJ,Spigel DR,et al.Molecular profiling diagnosis in unknown primary cancer:accuracy and ability to complement standard pathology[J].J Natl Cancer Inst,2013,105(11):782-790.
27 Kerr SE,Schnabel CA,Sullivan PS,et al.A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors[J].Mod Pathol,2014,27(1):44-54.
28 Kerr SE,Schabel CA,Sullivan PS,et al.Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier[J].Clin Cancer Res,2012,18(14):3952-3960.
29 Loffler H,Pfarr N,Kriegsmann M,et al.Molecular driver alterations and their clinical relevance in cancer of unknown primary site[J].Oncotarget,2016,7(28):44322-44329.
30 Ross JS,Wang K,Gay L,et al.Comprehensive genomic profiling of carcinoma of unknown primary site:new routes to targeted therapies[J].JAMA Oncol,2015,1(1):40-49.
31 Gatalica Z,Millis SZ,Vranic S,et al.Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site:Analysis of 1806 cases[J].Oncotarget,2014,5(23):12440-12447.
32 Ali SM,Sanford EM,Klempner SJ,et al.Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies[J].Oncologist,2015,20(5):499-507.
33 Varadhachary G.Carcinoma of unknown primary site:the poster child for personalized medicine? [J].JAMA Oncol,2015,1(1):19-21.
34 Kamposioras K,Pentheroudakis G,Pavlidis N.Exploring the biology of cancer of unknown primary:breakthroughs and drawbacks[J].Eur J Clin Invest,2013,43(5):491-500.
35 Nystrom SJ,Hornberger JC,Varadhachary GR,et al.Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer:impact on diagnosis,treatment,and survival[J].Oncotarget,2012,3(6):620-628.
36 Hainsworth JD,Schnabel CA,Erlander MG,et al.A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile[J].Clin Colorectal Cancer,2012,11(2):112-118.
37 Hainsworth JD,Rubin MS,Spigel DR,et al.Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site:a prospective trial of the Sarah Cannon research institute[J].J Clin Oncol,2013,31(2):217-223.
38 Gross-goupil M,Massard C,Lesimple T,et al.Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary(CUP):a feasibility study from the GEFCAPI[J].Oncologie,2012,35(1/2):54-55.
39 Le Tourneau C,Delord JP,Goncalves A,et al.Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer(SHIVA):a multicentre,open-label,proof-of-concept,randomised,controlled phase 2 trial[J].Lancet Oncol,2015,16(13):1324-1334.
40 Yoon HH,Foster NR,Meyers JP,et al.Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin,paclitaxel,and everolimus:NCCTG N0871(alliance)[J].Ann Oncol,2016,27(2):339-344.
41 National Cancer Institute.Molecular profiling-based assignment of cancer therapy for patients with advanced solid tumors[DB/OL].https://clinicaltrials.gov/ct2/show/NCT01827384?term=NCT01827384&rank=1,2017.
42 Anderson Cancer Center.Randomized study evaluating molecular profiling and targeted agents in metastatic cancer[DB/OL].https://clinicaltrials.gov/ct2/show/NCT0215
2254?term=IMPACT2&rank=4,2017.
43 Gustave Roussy,Cancer Campus,Grand Paris.Trial comparing a strategy based on molecular analysis to the empiric strategy in patients sith CUP[DB/OL].https://clinicaltrials.gov/ct2/show/NCT01540058?term=GEFCAPI04&rank=1,2017.
44 Hannouf MB,Winquist E,Mahmud SM,et al.Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary[J].Pharmacogenomics J,2017,17(3):286-300.

[1]	李吉, 陈杨, 张茂镕, 杨昭, 唐娴, 文洪梅. 中国常见消化系统恶性肿瘤伤残调整寿命年归因于人口老龄化的比例分析和趋势预测[J]. 实用肿瘤学杂志, 2025, 39(5): 372-380.
[2]	周素霞, 许志华, 郭淑玲, 范宁, 徐莉立. 2014—2021年青海省肿瘤登记地区恶性肿瘤发病与死亡流行趋势分析[J]. 实用肿瘤学杂志, 2025, 39(5): 381-387.
[3]	任方晗, 祝天岑, 礼彦侠, 陈丽莉, 那军, 田园梦, 穆慧娟. 2016—2020年辽宁省肿瘤登记地区淋巴瘤发病与死亡情况及其变化趋势分析[J]. 实用肿瘤学杂志, 2025, 39(5): 388-392.
[4]	刘璐, 朱佳禾, 王佳, 张博伦, 邢德皓, 丁高恒, 魏兴民, 刘玉琴. 2010—2021年甘肃省肿瘤登记地区食管癌发病趋势及年龄-时期-队列模型预测分析[J]. 实用肿瘤学杂志, 2025, 39(5): 393-399.
[5]	刘洋, 王颖, 马祥, 宋家宝, 刘大民, 陈丽莉. 2021年辽宁省营口市城市居民恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2025, 39(5): 400-404.
[6]	李芸, 史萍慧. 云南省个旧市胃癌高危人群的筛查与随访结果分析[J]. 实用肿瘤学杂志, 2025, 39(5): 405-411.
[7]	李一凡, 秦川玉, 曾玺, 陆娅胶, 廖光东, 康乐妮, 杨英, 周敏, 郄明蓉, 杨春霞, 李静. 宫颈癌筛查人群对自取样尿液HPV检测的接受度及影响因素分析[J]. 实用肿瘤学杂志, 2025, 39(5): 412-417.
[8]	李旭东, 刘通. 单细胞转录组揭示PCLAF与ERO1A在乳腺癌进展中的作用及预后价值[J]. 实用肿瘤学杂志, 2025, 39(5): 418-427.
[9]	张轩, 李娟, 方传丰, 田虹, 刘家仁. 植物化学物在肿瘤免疫治疗中的研究进展[J]. 实用肿瘤学杂志, 2025, 39(5): 428-432.
[10]	辛鑫, 熊文婧, 张春暖, 李晓静, 高雪, 张悦. 乳酸化修饰:癌症治疗中的新兴靶点[J]. 实用肿瘤学杂志, 2025, 39(5): 433-436.
[11]	周晴, 王雅梅. 口腔腺样囊性癌的表观遗传学调控机制研究进展[J]. 实用肿瘤学杂志, 2025, 39(5): 437-444.
[12]	罗淇元, 邵泓超, 周绍华, 叶木石. 前列腺癌术后腹股沟疝的发病机制、影响因素及外科防治策略的研究现状与展望[J]. 实用肿瘤学杂志, 2025, 39(5): 445-449.
[13]	吕睿, 甄林林. 骨微环境介导乳腺癌骨转移耐药性的研究进展[J]. 实用肿瘤学杂志, 2025, 39(5): 450-456.
[14]	李吉, 张茂镕, 杨昭, 文洪梅, 伍福仙, 李云涛. 2020年云南省昆明市肿瘤登记地区恶性肿瘤发病和死亡特征及2016—2020年趋势分析[J]. 实用肿瘤学杂志, 2025, 39(3): 169-176.
[15]	赵恩桐, 关心, 李洪艳, 邱韵婷, 张炳强, 陈梦梦, 邹伟, 屈超. SNG162通过上调ER-α36表达激活胶质母细胞瘤膜起始的雌激素信号通路[J]. 实用肿瘤学杂志, 2025, 39(3): 177-183.